Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: A review of ticagrelor

Clinical Pharmacology: Advances and Applications

Volumn 5, Issue , 2013, Pages 67-83

  Davis, Estella M ^a   Knezevich, Jon T ^a   Teply, Robyn M ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

Author keywords

Acute coronary syndrome; Antiplatelet; Non ST elevation MI; Percutaneous coronary intervention; ST elevation myocardial infarction; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; CYTOCHROME P450 2C19; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIRULOG; PLACEBO; PRASUGREL; QUINIDINE; TICAGRELOR; TIROFIBAN; URIC ACID;

ACUTE CORONARY SYNDROME; ALLELE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; FAINTNESS; HEART ARREST; HUMAN; KIDNEY DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORBIDITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PHARMACOGENOMICS; REVIEW; RISK REDUCTION; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS; URIC ACID BLOOD LEVEL;

EID: 84876998756     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S41859     Document Type: Review

References (94)

1. World Health Organization. Top Ten Causes of Death. Geneva: World Health Organization; 2011. Available from: http://www.who.int/ mediacentre/factsheets/fs310_2008.pdf. Accessed December 14, 2012.
2. Behan M W, Chew D P, Aylward PE. The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Curr Opin Cardiol. 2010;25(4):321-328.
3. Marczewski MM, Postula M, Kosior D. Novel antiplatelet agents in the prevention of cardiovascular complications - focus on ticagrelor. Vasc Health Risk Manag. 2010;6:419-429.
4. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharma-codynamic and clinical profle of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol. 2010;159(3):502-517.
5. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/ non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012;126(7):875-910.
6. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(33):e574-e651.
7. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-e140.
8. Hamm C W, Bassand J P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999-3054.
9. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31(20):2051-2055.
10. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-2619.
11. Zhou D, Andersson TB, Grimm S W. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phe-notyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011;39(4):703-710.
12. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38(9):1514-1521.
13. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66(5):487-496.
14. Gurbel PA, Bliden K P, Butler K, et al. Response to ticagrelor in clopi-dogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188-1199.
15. Husted S, Emanuelsson H, Hepinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038-1047.
16. Gurbel PA, Bliden K P, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary disease: the ONSET/OFFSET study. Circulation. 2009;120(25): 2577-2585.
17. Storey R F, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (Platelet Inhibitions and Patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56(18): 1456-1462.
18. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol. 2010;70(1):65-77.
19. Teng R, Mitchell PD, Butler K. Lack of signifcant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. J Clin Pharm Ther. 2012;37(4):464-468.
20. Brilinta® (ticagrelor) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2013.
21. Effent™ (prasugrel) [package insert]. Indianapolis, IN: Eli Lilly and Co; 2012.
22. Plavix® (clopidogrel bisulfate) [package insert]. Bridgewater, NJ: Sanof-Aventis US; 2011.
23. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol. 2012;52(9):1388-1398.
24. University of Patras. Ticagrelor in clopidogrel resistant patients undergoing chronic hemodialysis. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated February 2, 2012]. Available from: http://clinicaltrials. gov/show/NCT01511471.NLMidentifer:NCT01511471. Accessed December 14, 2012.
25. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment. J Clin Pharmacol. 2011;51(7):978-987.
26. Teng R, Mitchell P, Butler K. Effect of age and gender on pharmacoki-netics and pharmacodynamics of a single ticagrelor dose in healthy individuals. Eur J Clin Pharmacol. 2012;68(8):1175-1182.
27. AstraZeneca. An Asian study to assess the properties and profle of ticagrelor in patients with stable coronary artery disease. In: ClinicalTri-als.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated April 13, 2012]. Available from: http://clinicaltrials.gov/show/NCT01118325.NLMidentifer:NCT01118325. Accessed December 14, 2012.
28. AstraZeneca. A pharmacodynamics study with ticagrelor in African American patients. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated February 4, 2013]. Available from: http://clinicaltrials.gov/ show/NCT01523392. NLM identifier: NCT01523392. Accessed December 14, 2012.
29. AstraZeneca. A pharmacodynamic study with ticagrelor in Hispanic patients. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated February 4, 2013]. Available from: http://clinicaltrials.gov/show/NCT01523366.NLMidentifer:NCT01523366. Accessed December 14, 2012.
30. AstraZeneca. Study to assess safety and efficacy of ticagrelor (AZD6140) versus clopidogrel in Asian/Japanese patients with non-ST or ST elevation acute coronary syndromes (ACS). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated August 17, 2012]. Available from: http://clinicaltrials.gov/show/NCT01294462.NLMidentifer:NCT01294462. Accessed December 14, 2012.
31. Rapid City Regional Hospital; AstraZeneca. Antiplatelet effects of ticagrelor versus clopidogrel in American Indian patients. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012. Available from: http://clinicaltrials.gov/ show/NCT01706510. NLM identifier: NCT01706510. Accessed December 14, 2012.
32. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11): 1045-1057.
33. Mahaffey K W, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124(5):544-554.
34. Brilinta™ (ticagrelor) tablets REMS. [homepage on the Internet]. Available from: http://www.brilintarems.com. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2011. Accessed December 14, 2012.
35. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50(19):1852-1856.
36. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5(6):797-804.
37. Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol. 2012;60(3):193-199.
38. Bonello L, Tantry US, Marcucci R, et al. Consenus and future directions on the defnition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919-933.
39. Badimon JJ; AstraZeneca. Antithrombotic effects of ticagrelor versus clopidogrel. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012. Available from: http://clinicaltrials.gov/show/NCT01642238.NLMidentifer:NCT01642238. Accessed December 14, 2012.
40. Pusan National University Yangsan Hospital; AstraZeneca. Comparison of antiplatelet effect of ticagrelor vs tirofban in patients with non-ST elevation acute coronary syndrome (TE-CLOT). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated December 16, 2012]. Available from: http://clinicaltrials.gov/show/NCT01660373.NLMidentifer:NCT01660373. Accessed December 14, 2012.
41. AstraZeneca. Ad hoc percutaneous coronary intervention study in acute coronary syndrome patients. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated January 15, 2013]. Available from: http://clinicaltrials.gov/show/NCT01603082.NLMidentifer:NCT01603082. Accessed December 14, 2012.
42. Careggi Hospital. Rapid activity of platelet inhibitor drugs study (RAPID). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated January 13, 2012]. Available from: http://clinicaltrials.gov/show/NCT01510171.NLMidentifer:NCT01510171. Accessed December 14, 2012.
43. University of Patras. Standard (180 mg) versus double (360 mg) loading dose of ticagrelor in patients with ST-elevation myocardial infarction (STEMI), undergoing primary percutaneous coronary intervention (PCI). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated April 10, 2012]. Available from: http://clinicaltrials.gov/show/NCT01575795.NLMidentifer:NCT01575795. Accessed December 14, 2012.
44. Rabin Medical Center. Effect of modifying anti-platelet treatment to ticagrelor in patients with diabetes and low response to clopidogrel (MATTIS-D). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated July 17, 2012]. Available from: http://clinicaltrials.gov/show/NCT01643031.NLMidentifer:NCT01643031. Accessed December 14, 2012.
45. Deutsches Herzzentrum Muenchen. Intracoronary stenting and antithrombotic regimen: adjusting antiplatelet treatment in patients based on platelet function testing (ISAR ADAPT PF). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/ show/NCT01456364. NLM identifier: NCT01456364. Accessed December 14, 2012.
46. Clinical Center of Serbia. On-treatment platelet reactivity-guided therapy modifcation for ST-segment elevation myocardial infarction (PLATFORM). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated November 30, 2012]. Available from: http://clinicaltrials.gov/ show/NCT01739556. NLM identifier: NCT01739556. Accessed December 14, 2012.
47. University of Patras. Differential effect of ticagrelor versus prasugrel on the adenosine-induced coronary vasodilatory responses in patients with acute coronary syndrome undergoing percutaneous coronary intervention. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated January 21, 2013]. Available from: http://clinicaltrials.gov/show/NCT01642966.NLMidentifer:NCT01642966. Accessed December 14, 2012.
48. Johannes Gutenberg University Mainz. Endothelium, stenting, and antiplatelet therapy (EST) - clopidogrel, prasugrel, ticagrelor study. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated October 11, 2012]. Available from: http://clinicaltrials.gov/show/NCT01700322.NLMidentifer:NCT01700322. Accessed December 14, 2012.
49. Assistance Publique Hopitaux De Marseille. Evaluation of ticagrelor antiplatelet and pleiotropic effects in patients undergoing percutaneous coronary intervention for an acute coronary syndrome. In: ClinicalTri-als.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated June 20, 2012]. Available from: http://clinicaltrials.gov/show/NCT01626534.NLMidentifer:NCT01626534. Accessed December 14, 2012.
50. University of Texas Southwestern Medical Center; AstraZeneca. A trial comparing the ischemic preconditioning effects of ticagrelor and clopidogrel in humans (ETCH). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated December 4, 2012]. Available from: http://clinicaltrials. gov/show/NCT01743937.NLMidentifer:NCT01743937. Accessed December 14, 2012.
51. Hyeon-Cheol Gwon. Ticagrelor and intracoronary morphine in patients undergoing primary percutaneous coronary intervention. In: ClinicalTri-als.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated November 29, 2012]. Available from: http://clinicaltrials.gov/show/NCT01738100.NLMidentifer:NCT01738100. Accessed December 14, 2012.
52. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4): 354-362.
53. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010;122(5):537-557.
54. Chandrasekar S, Loomba R, Shah P, Arora R. Ideal antiplatelet therapy for coronary artery disease: focus on adenosine diphosphate receptor inhibitors. Am J Ther. April 23, 2011; [Epub ahead of print.]
55. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to phar-macokinetic, pharmacodynamics, and clinical outcomes. Circulation. 2009;119(19):2553-2560.
56. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamics responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009;30(14):1744-1752.
57. University of Roma La Sapienza. High clopidogrel dose versus prasugrel and ticagrelor in high reactive stable patients (TRIPLETE RESET). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated December 4, 2012]. Available from: http://clinicaltrials.gov/show/NCT01543932.NLMidentifer:NCT01543932. Accessed December 14, 2012.
58. Italian Society of Invasive Cardiology. Customized choice of oral P2Y12 receptor blocker (GENE-MATRIX). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated November 5, 2012]. Available from: http://clinicaltrials. gov/show/NCT01477775.NLMidentifer:NCT01477775. Accessed December 14, 2012.
59. Mayo Clinic. Tailored antiplatelet therapy following PCI (TAILOR-PCI). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012. Available from: http://clinicaltrials. gov/show/NCT01742117.NLMidentifer:NCT01742117. Accessed December 14, 2012.
60. Cannon C P, Husted S, Harrington RA, et al. Safety, tolerability, and initial effcacy of AZD6140, the frst reversible oral adenosine diphos-phate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50(19):1844-1851.
61. Center for Drug Evaluation and Research. Ticagrelor: Complete Response Review Addenum. Silver Spring, MD: US Food and Drug Administration; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ nda/2011/022433Orig1s000MedR.pdf. Accessed January 5, 2013.
62. Cannon C P, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. Lancet. 2010;375(9711):283-293.
63. James SK, Row MT, Cannon C P, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. BMJ. 2011;342:d3527.
64. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122(21):2131-2141.
65. Held C, Asenblad N, Bassand J P, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57(6):672-684.
66. Varenhorst C, Alstrom U, Scirica B, et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2012; 60(17):1623-1630.
67. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056-1067.
68. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Eur Heart J. 2010;31(24):3006-3016.
69. DiNicolantonio JJ, Serebruany VL. Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor- angiotensin receptor blocker interaction? Clin Cardiol. 2012;35(11): 647-648.
70. James SK, Storey R F, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation. 2012;125(23):2914-2921.
71. Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012;5(5):680-688.
72. Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnea in PLATO study patients treated with ticagrelor or clopidogrel in its association with clinical outcomes. Eur Heart J. 2011;32(23):2945-2953.
73. Storey FR, Becker RC, Harrington RA, et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol. 2011;108(11): 1542-1546.
74. Storey RF, Bliden K P, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010;56(3):185-193.
75. Nawarskas JJ, Snowden SS. Critical appraisal of ticagrelor in the management of acute coronary syndrome. Ther Clin Risk Manag. 2011;7: 473-488.
76. Scirica BM, Cannon C P, Emanuelsson H, et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011;57(19):1908-1916.
77. AstraZeneca. A 30 day study to evaluate effcacy and safety of pre-hospital versus in-hospital initiation of ticagrelor therapy in STEMI patients planned for percutaneous coronary intervention (PCI) (ATLANTIC). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated December 20, 2012]. Available from: http://clinicaltrials.gov/show/NCT01347580.NLMidentifer:NCT01347580. Accessed December 14, 2012.
78. Maasstad Hospital. Randomized, open label trial of 6 months versus 12 months DAPT after drug-eluting stent in STEMI (DAPT-STEMI). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated December 17, 2012]. Available from: http://clinicaltrials.gov/show/NCT01459627.NLMidentifer:NCT01459627. Accessed December 14, 2012.
79. Boston Scientifc Corporation. PROMUS Element Plus US post- approval study. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated October 17, 2012]. Available from: http://clinicaltrials.gov/show/NCT01589978.NLMidentifer:NCT01589978. Accessed December 14, 2012.
80. Marco Valgimigli. Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates (ZEUS) study. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated October 6, 2012]. Available from: http://clinicaltrials. gov/show/NCT01385319.NLMidentifer:NCT01385319. Accessed December 14, 2012.
81. Biondi-Zoccai G, Lotrionte M, Agostoni P, et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol. 2011;150(3):325-331.
82. Navarese E P, Verdoia M, Schaffer A, et al. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM. 2011;104(7):561-569.
83. Steiner S, Moertl D, Chen L, Coyle D, Wells GA. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thromb Haemost. 2012;108(2):318-327.
84. European Medicines Agency. Brilique: Summary of Product Characteristics. London: European Medicines Agency; 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/001241/WC500100494.pdf. Accessed December 14, 2012.
85. Brilinta® (ticagrelor) [product monograph]. Mississauga, ON: AstraZeneca Canada; 2011.
86. Serebruany VL. Adenosine release: a potential explanation for the benefts of ticagrelor in the Platelet Inhibition and Clinical Outcomes trial. Am Heart J. 2011;161(1):1-4.
87. Agewall S, Badimon L, Drouet L, et al. Oral antiplatelet agents in ACS: from pharmacology to clinical differences. Fundam Clin Pharmacol. 2011;25(5):564-571.
88. Scneider DJ. Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy. J Am Coll Cardiol. 2011;57(6):685-687.
89. Nikolic E, Janzon M, Hauch O, et al. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J. 2013;34(3):220-228.
90. Crespin DJ, Federspiel JJ, Biddle AK, Jonas DE, Rossi JS. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. Value Health. 2011;14(4):483-491.
91. Mehta SR, Tanguay J F, Eikelboom J W, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233-1243.
92. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-1105.
93. Collet J P, Cuisset T, Range G, et al. Bedside monitoring to adjust anti-platelet therapy for coronary stenting. N Engl J Med. 2012;367(22): 2100-2109.
94. Trenk D, Stone G W, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidgorel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159-2164.